- All Courts
- Federal Courts
- Bankruptcies
- PTAB
- ITC
Filters
Like full text docket searches?
Get docket alerts, perform legal research, get updates of major decisions and orders, use our advanced analytics, and more. Request a Demo or create your account.
Date Filed
Dollars
Find cases based on dollar amount with searches like:
$100k-$10M.
Read the details here.
Displaying 174-188 of
231 results
2028 Exhibit: World Intell Prop Org Patent Application No WO 02077029 A2
Document
IPR2022-00853, No. 2028-72 Exhibit - World Intell Prop Org Patent Application No WO 02077029 A2 (P.T.A.B. Jul. 19, 2022)
|
|
Cite Document
2008 Exhibit: FOOD AND DRUG ADMIN, BREAKTHROUGH THERAPY Jan 4, 2018...
Document
IPR2022-00853, No. 2008-52 Exhibit - FOOD AND DRUG ADMIN, BREAKTHROUGH THERAPY Jan 4, 2018, httpswwwfdagovpatientsfast track breakthrough therapy accelerated approval priorit...
|
|
Cite Document
2042 Exhibit: US Patent No 7,402,431
Document
IPR2022-00853, No. 2042-86 Exhibit - US Patent No 7,402,431 (P.T.A.B. Jul. 19, 2022)
|
|
Cite Document
2034 Exhibit: David L Porter et al, A phase 1 trial of donor lymphocyte infusions exp...
Document
IPR2022-00853, No. 2034-78 Exhibit - David L Porter et al, A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3CD28 costimulation, 107 BLOOD 1325 2006 (P.T...
|
|
Cite Document
2018 Exhibit: David L Porter et al, Randomized, Phase II Dose Optimization Study O...
Document
IPR2022-00853, No. 2018-62 Exhibit - David L Porter et al, Randomized, Phase II Dose Optimization Study Of Chimeric Antigen Receptor Modified T Cells Directed Against CD 19 CTL019 In Patie...
|
|
Cite Document
2037 Exhibit: Bipulendu Jena et al, Redirecting T cell specificity by introducing a tum...
Document
IPR2022-00853, No. 2037-81 Exhibit - Bipulendu Jena et al, Redirecting T cell specificity by introducing a tumor specific chimeric antigen receptor, 116 BLOOD 1035 2010 (P.T.A.B. Jul. 19, 2022...
|
|
Cite Document
2019 Exhibit: Stephan A Grupp et al, T Cells Engineered With A Chimeric Antigen R...
Document
IPR2022-00853, No. 2019-63 Exhibit - Stephan A Grupp et al, T Cells Engineered With A Chimeric Antigen Receptor CAR Targeting CD 19 CTL0l 9 Produce Significant In Vivo Proliferation, Comp...
|
|
Cite Document
2039 Exhibit: Cor HJ Lamers et al, Treatment of Metastatic Renal Cell Carcinoma W...
Document
IPR2022-00853, No. 2039-83 Exhibit - Cor HJ Lamers et al, Treatment of Metastatic Renal Cell Carcinoma With Autologous T Lymphocytes Genetically Retargeted Against Carbonic Anhydrase IX...
|
|
Cite Document
2038 Exhibit: Michael H Kershaw et al, A Phase I Study on Adoptive Immunotherap...
Document
IPR2022-00853, No. 2038-82 Exhibit - Michael H Kershaw et al, A Phase I Study on Adoptive Immunotherapy Using Gene Modified T Cells for Ovarian Cancer, 12 CLINICAL CANCER RSCH 6106...
|
|
Cite Document
2031 Exhibit: Steven A Rosenberg et al, Use of Tumor Infiltrating Lymphocytes and...
Document
IPR2022-00853, No. 2031-75 Exhibit - Steven A Rosenberg et al, Use of Tumor Infiltrating Lymphocytes and Interleukin 2 in the Immunotherapy of Patients with Metastatic Melanoma, 319 NEW E...
|
|
Cite Document
2014 Exhibit: Renier J Brentjens et al, A Phase I Trial for the Treatment of Chemo re...
Document
IPR2022-00853, No. 2014-58 Exhibit - Renier J Brentjens et al, A Phase I Trial for the Treatment of Chemo refractory Chronic Lymphocytic Leukemia with CD19 Targeted Autologous T Cells, 16 M...
|
|
Cite Document
2031 Exhibit: Steven A Rosenberg et al, Use of Tumor Infiltrating Lymphocytes and...
Document
IPR2022-00853, No. 2031-75 Exhibit - Steven A Rosenberg et al, Use of Tumor Infiltrating Lymphocytes and Interleukin 2 in the Immunotherapy of Patients with Metastatic Melanoma, 319 NEW E...
|
|
Cite Document
2001 Exhibit: Jason Fagone, Has Carl June Found a Key to Fighting Cancer, PHILA...
Document
IPR2022-00853, No. 2001-45 Exhibit - Jason Fagone, Has Carl June Found a Key to Fighting Cancer, PHILA MAG Aug 1, 2013 (P.T.A.B. Jul. 19, 2022)
|
|
Cite Document
2016 Exhibit: Jennifer Couzin Frankel, Breakthrough of the Year 2013 Cancer Imm...
Document
IPR2022-00853, No. 2016-60 Exhibit - Jennifer Couzin Frankel, Breakthrough of the Year 2013 Cancer Immunotherapy, 342 SCI 1432 2013 (P.T.A.B. Jul. 19, 2022)
|
|
Cite Document
2015 Exhibit: Jennifer Couzin Frankel, The dizzying journey to a new cancer arsena...
Document
IPR2022-00853, No. 2015-59 Exhibit - Jennifer Couzin Frankel, The dizzying journey to a new cancer arsenal, 340 SCI 1514 2013 (P.T.A.B. Jul. 19, 2022)
|
|
Cite Document
